To see all protocols that comply with the WHO Essential Medicine List 

Treatment schedule

Dose 2 onwards

Drug Dose Route
Rituximab 1,400 mg Subcut


  • All patients must always receive their first dose of rituximab by intravenous (IV) administration, using the IV formulation (375 mg/m2).
  • The subcutaneous regimen is ONLY to be used in patients who are receiving their second or subsequent dose of rituximab and who received their previous dose/s without grade 3 or 4 infusion-related toxicities.
  • The recommended dosage is a fixed dose of 1,400 mg (NHL) irrespective of the patient's body surface area (BSA).

While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

27 Jan 2020